Shares of Novo Nordisk A/S (NVO.US) rose 6% on Monday, trading at $45.79.
The increase follows a recent statement from the company's CEO clarifying that the regulatory data protection period for its blockbuster drug semaglutide in China will now last until April 2027. This date extends the market exclusivity by over a year beyond the core compound patent's expiration in March 2026.
Estimates suggest this additional 13-month protection period is expected to generate approximately $1 billion in stable, incremental cash flow for the pharmaceutical firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments